RAPT Insider Trading
Insider Ownership Percentage: 6.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
RAPT Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at RAPT Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
RAPT Therapeutics Share Price & Price History
Current Price: $1.18
Price Change: ▼ Price Decrease of -0.045 (-3.69%)
As of 04/1/2025 04:59 PM ET
RAPT Therapeutics Insider Trading History
RAPT Therapeutics Institutional Trading History
Data available starting January 2016
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company
Read More on RAPT Therapeutics
Volume
618,614 shs
Average Volume
1,274,487 shs
Market Capitalization
$155.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of RAPT Therapeutics?
Who are the major institutional investors of RAPT Therapeutics?
Which institutional investors are selling RAPT Therapeutics stock?
During the last quarter, RAPT stock was sold by these institutional investors:
- Column Group LLC
- Two Sigma Investments LP
- D. E. Shaw & Co. Inc.
- Millennium Management LLC
- Two Sigma Advisers LP
- Dimensional Fund Advisors LP
- Jane Street Group LLC
- Deutsche Bank AG
Which institutional investors are buying RAPT Therapeutics stock?
During the previous quarter, RAPT stock was bought by institutional investors including:
- Medicxi Ventures Management Jersey Ltd
- Orbimed Advisors LLC
- TCG Crossover Management LLC
- Foresite Capital Management VI LLC
- RTW Investments LP
- BVF Inc. IL
- Deep Track Capital LP
- Redmile Group LLC